New cancer drug PRO1160 tested in advanced cancers – trial ends early

NCT ID NCT05721222

Terminated Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRO1160 (GEN1160)
What this could lead to: If successful, this could point toward a new treatment option for certain advanced cancers that have not responded to other therapies.
What could go wrong: This trial was terminated early, so results are limited. It is an early-phase study, so safety and effectiveness are not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma mantle cell lymphoma nasopharyngeal carcinoma non-Hodgkin lymphoma nonpapillary renal cell carcinoma papillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA NON-HODGKIN LYMPHOMA RENAL CELL CARCINOMA

Contacts and locations

Locations

Cancer Hospital of Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China
City of Hope Comprehensive Cancer Center - Duarte

Duarte, California, 91010, United States
Cleveland Clinic - Euclid Hospital

Cleveland, Ohio, 44195, United States
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Levine Cancer Center

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Montefiore Medical Center - Montefiore Hospital

The Bronx, New York, 10467, United States
NYU Langone Health

New York, New York, 10016, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China
START Mountain Cancer Center

West Valley City, Utah, 84119, United States
Sarah Cannon Research Institute - Nashville

Nashville, Tennessee, 37203, United States
The City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, 92618, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
Washington University School of Medicine in St. Louis

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.